CROs offering Immunogenicity Assays (ADA / NAb) with mRNA
8 published
8 published CROs match Immunogenicity Assays (ADA / NAb) and mRNA.
Locations in this set include United States, China, India, Netherlands, South Korea, and Belgium.
Capabilities that show up most often in this set: Bioanalysis, Analytical Method Development & Validation, Biomarker Assays, Flow Cytometry Services, and LC-MS Bioanalysis (Small Molecule).
Matching companies
Amador BioscienceAmador Bioscience provides bioanalysis and biomarker services, including LCMS, immunoassays, flow cytometry, and immunogenicity testing, alongside clinical pharmacology modeling and regulatory affairs support. Its labs are GLP compliant, and its teams work across the US, China, and Europe.
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Avance BiosciencesAvance Biosciences is a CRO and contract testing organization offering CGMP- and GLP-compliant analytical and bioanalytical services for drug development. Services cover preclinical and clinical studies, CMC support, CLIA testing, and assay development.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
ProBioProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.
SoCal Biosciences, Inc.San Diego-based bioanalytical CRO specializing in assay development and analysis for mRNA, oligonucleotides, and large molecules across discovery through clinical development phases.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/immunogenicity-assays/mrna.md